Posted by Michael Wonder on 06 Mar 2022
U.S. Food and Drug Administration approves Opdivo (nivolumab) with chemotherapy as neo-adjuvant treatment for certain adult patients with resectable non-small cell lung cancer
4 March 2022 - Approval marks the first and only immunotherapy-based treatment for use before surgery for non-small cell lung cancer.
Bristol Myers Squibb today announced that the U.S. FDA approved Opdivo (nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks for three cycles for adult patients with resectable (tumours ≥4 cm or node positive) non-small cell lung cancer in the neo-adjuvant setting.
